Previous close | 0.0500 |
Open | 0.0500 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 0.0500 - 0.0500 |
52-week range | 0.0350 - 0.1340 |
Volume | |
Avg. volume | 2,534 |
Market cap | 3.94M |
Beta (5Y monthly) | 0.49 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0400 |
Earnings date | 29 May 2024 - 03 Jun 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ChitogenX Inc., (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced that it has launched a new development program targeting significant unmet medical needs in the burn and skin repair market, currently valued at US $19B and growing at 5% + CAGR through 2032. Proof of concept studies have already been successfully completed and results will be the subject of news releases in the coming weeks.